BBNX Stock Forecast & Price Target

Beta Bionics is well positioned to compound revenue as its differentiated iLet closed-loop system continues to gain adoption, with Q3 revenue of $35.5M, up about 30% year over year, and roughly 10% NRx share underscoring early traction in a large pump market. Management’s raised 2026 revenue outlook to $124M-$126M, plus the planned Mint patch pump launch in 1Q27 and 1.5M+ unit capacity in FY27, supports a credible path to further share gains, broader pharmacy-channel penetration, and eventual profitability. Although gross margin is expected to dip in 2027 as Mint ramps, the pipeline breadth, including 3D Intelligence and bihormonal development, strengthens long-term growth visibility and justifies a constructive fundamental view.

Beta Bionics is facing a weaker-than-expected gross margin profile, with 57.3% gross margins below Street, TD Cowen, and BBNX expectations as unfavorable mix from lower-margin DME supplies and distributor stocking dynamics offset higher-margin iLet revenue. The regulatory setback on the 3D Intelligence Algorithm is also a major overhang, since the company withdrew its 510(k) submission at the FDA’s request and now expects a revised filing in mid-Q4 2026, pushing launch expectations for iLet 3D and Mint 3D to mid-2027. Combined with risks around slower pump penetration, weaker pharmacy-channel adoption, potential FDA actions, and possible capital needs that could dilute shareholders, the fundamental outlook remains pressured.